HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections. Human studies showed that the TGF-β trap and IL-15 fusion promoted expansion of progenitor CD8+ T cells and Natural Killer ("NK") cells, provided clinical benefit, and was well tolerated in cancer patients. In addition, the fusion demonstrated activity against HIV-1 and bronchopulmonary dysplasia in highly stringent, relevant animal models. Several publications in leading scientific journals include extensive human and animal study data regarding the TGF-β trap and IL-15 fusion.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.